News and Trends 15 Apr 2021
Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of…